After 30+ years of clinical experience with clozapine, it is time for professional psychiatry to demand an end to this discriminatory clozapine REMS program.

What is the reality of patient resilience?

How can we enhance our connection to the world and each other?

The vice president of Clinical Development and Medical Affairs, Mental Health at Boehringer Ingelheim shares why it is such an unprecedented moment for schizophrenia research.

Eating pros vs those with eating disorders: what’s the difference?

Cobenfy: Only the first in a new upcoming class of antipsychotics.

While there is still a lot to learn about Cobenfy, here's why it marks a historic moment in the treatment of schizophrenia.

A traumatic brain injury sustained earlier in adult life is likely to interact with normal aging processes. Learn more here.

What can we learn from artists’ memoirs?

Multiple sites are now enrolling participants in a phase 2 clinical trial to evaluate SPG302, the first synaptic regenerative therapy for schizophrenia.

Where do we draw the line on level of impairment for our presidential candidates?

This celebration of the creativity of the arts comes at a time when the arts have been cut in school education and in psychiatry.

The first-in-class muscarinic agonist Cobenfy, formerly known as KarXT, was just approved by the FDA to treat schizophrenia in adults. Are you ready to discuss it with patients and caregivers?

Does reduced blood monitoring impact the detection of hematological abnormalities in clozapine-treated patients? Researchers performed a chart review study from the COVID-10 pandemic.

"A single gem has throbbed in my chest my whole life, even though, even though this is my second heart..."

How can we protect the mental health of our country?

The US Food and Drug Administration approves Cobenfy (KarXT), the first new agent with a novel mechanism of action for schizophrenia more than 50 years.

Mental health clinicians can help empower patients via tools like diet, including the MIND Diet.

This book seeks to reduce the stigma surrounding teen pregnancy.

Enter your email to see the results of our polls on social media usage amongst mental health clinicians!

Psychiatrists and mental health clinicians: a social determinant of health.

Celebrating 4 years of Psychiatry & Society!

Experts in the management of mood disorders comment on the evolving management of major depressive disorder, emphasizing findings from the STAR*D trial, updated treatment guidelines, and the role of precision medicine and the shift toward personalized, rapid-acting treatments to improve patient outcomes.

With art we build what poverty destroys.

Gus Alva, MD, DFAPA, introduces his esteemed colleagues and leads a comprehensive discussion on the complexities of managing major depressive disorder. The conversation addresses the rising prevalence of MDD, the enduring stigma surrounding the condition, and its profound impact on patient quality of life.